Clinical Trials & Treatments

At the Houston Methodist Kenneth R. Peak Brain and Pituitary Tumor Treatment and Research Center, we offer aggressive treatment and access to research studies in the management of brain cancer. Examples of potential research studies include gene therapy, immune therapy and the use of personalized tumor vaccines made from tumor tissue obtained during surgery. The results from these research studies may affect future clinical alternatives for all patients. 
A brief description of our most promising trials follows.

The purpose of this study is to determine if treatment with Toca 511, an investigational product, is safe and well tolerated.  Toca 511 is a live virus that has been built to carry a gene into cancer cells. This is called gene transfer.  This gene carries instructions that cause the cancer cells to turn the flucytosine (5-FC) that you will be given into a chemical that may kill the cancer cells. Read more >

NovoCure EF-14
The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrodes. Read more >

A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) 
pulsed with tumor lysate antigen for the treatment of Glioblastoma multiforme (GBM) – Consent for Brain Study

The purpose of this study is to determine the effectiveness and safety of an investigational agent called DCVax®-L which is made from your own blood cells which have been exposed to the patient’s own tumor tissue. Moreover, it will determine whether DCVax®-L  can slow the growth and recurrence of your brain tumor and whether DCVax®-L can extend overall survival.  Other goals of this trial are to test the safety and activity of DCVax®-L and to determine whether the study agent causes an immune response against your cancer cells as compared to standard treatment. Read more >

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma   NCT02546102
The purpose of this study is to  find out if adding treatment with an investigational medicine (ICT-107) helps to prevent brain tumors from coming back so soon after surgery, radiation, and chemotherapy and if it helps people with brain tumors live longer compared to standard treatment alone. Because this study involves research, there are certain outcomes that are unknown. Read more >

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study)
The purpose of this study is to find out whether adding treatment with rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug called temozolomide helps to shrink brain tumors or prevents brain tumors from growing and helps patients with brain tumors live longer than treatment with temozolomide alone. Read more >

For more information, please contact us at: 713.441.8500
Kenneth R. Peak Brain and Pituitary Tumor Treatment & Research Center 
Houston Methodist Hospital - Texas Medical Center
6445 Main Street, Outpatient Center, Floor 24
Houston, TX 77030